List of Excipients in Branded Drug POMALYST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Celgene Corporation	POMALYST	pomalidomide	59572-501	MANNITOL
Celgene Corporation	POMALYST	pomalidomide	59572-501	SODIUM STEARYL FUMARATE
Celgene Corporation	POMALYST	pomalidomide	59572-501	STARCH, CORN

# POMALYST Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

POMALYST (pomalidomide) is an oral, hard-gelatin capsule marketed by Bristol Myers Squibb for multiple myeloma and AIDS-related Kaposi sarcoma. Its excipient platform is relatively conventional: lactose-based capsule fill with starch, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate, packaged in color-coded gelatin capsules.[1] The largest commercial opportunities are in generic supply, excipient-grade optimization, capsule-shell materials, global formulation adaptation, and manufacturing support rather than in novel excipient claims.

What is the POMALYST formulation and which excipients does it contain?

POMALYST is supplied in 1 mg, 2 mg, 3 mg, and 4 mg capsules. The active pharmaceutical ingredient is pomalidomide, an immunomodulatory agent structurally related to thalidomide and lenalidomide.

The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Reported material	Commercial function
Diluent	Lactose monohydrate	Provides bulk and improves capsule-fill uniformity
Binder or filler	Pregelatinized starch	Supports powder cohesion and compactability
Surfactant	Sodium lauryl sulfate	Improves wetting and dispersion of the low-dose API
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces adhesion during manufacturing
Capsule shell	Gelatin	Encapsulates the powder blend
Colorants	Titanium dioxide and capsule-specific colorants	Product identification and strength differentiation

The label does not disclose quantitative excipient levels, particle-size specifications, grades, or suppliers.[1] Those parameters are typically controlled in the confidential chemistry, manufacturing, and controls file rather than the public label.

Pomalidomide is present at a low dose relative to the capsule fill. That makes blend uniformity, segregation control, electrostatic behavior, and API distribution more important than simple bulk capacity. Excipient selection must support content-uniformity testing across the full commercial batch.

What excipient functions are most important in POMALYST manufacturing?

Lactose monohydrate as the primary diluent

Lactose is likely the principal commercial-volume excipient in the reference formulation. Opportunities exist for suppliers offering:

• Consistent particle-size distributions
• Low-moisture grades
• Improved flow grades
• Low-endotoxin and high-purity material
• Global regulatory documentation
• Reliable supply from more than one qualified site

For a low-dose capsule, lactose particle size can affect API segregation and blend uniformity. A supplier that can provide narrow particle-size control, low variability, and strong lot-to-lot documentation may have greater value than a lower-cost commodity supplier.

Lactose also creates a commercial constraint. Patients with severe lactose intolerance may seek an alternative formulation, although the lactose quantity in a capsule may be small. A lactose-free generic or authorized alternative could have differentiation value if it maintains bioequivalence and avoids a material increase in capsule size.

Pregelatinized starch

Pregelatinized starch contributes binding and flow properties. It may help compensate for the poor handling characteristics often associated with low-dose active ingredients.

Commercial opportunities include:

• Direct-compression or capsule-grade starch
• Low-moisture grades for improved stability
• Starch with controlled flow and bulk density
• Regional starch sources qualified under the same specification
• Excipient systems designed for low-dose blend uniformity

A substitute starch could alter dissolution, water uptake, and blend segregation. The regulatory burden would depend on the formulation change, the applicant’s development strategy, and the extent of comparative dissolution and bioequivalence evidence.

Sodium lauryl sulfate

Sodium lauryl sulfate is a wetting agent. Its inclusion may improve dispersion of pomalidomide, which has limited aqueous solubility.

The excipient creates two commercial considerations. First, grade consistency matters because changes in surface activity can affect dissolution. Second, some manufacturers may seek to reduce or replace sodium lauryl sulfate because of tolerability concerns, surfactant sensitivity, or internal excipient policies.

Potential alternatives include poloxamers, sodium docusate, or other wetting systems. Each alternative would require formulation and regulatory work. A replacement is not a simple one-for-one substitution because surfactant concentration can affect dissolution profiles, impurity behavior, and capsule-fill processing.

Colloidal silicon dioxide and magnesium stearate

These are low-cost but process-critical materials.

Colloidal silicon dioxide controls flow and can reduce variability in capsule filling. Its performance depends on surface area, aggregation state, moisture, and mixing energy.

Magnesium stearate reduces friction and tooling adhesion. Excessive lubrication or overmixing can create hydrophobic surfaces and slow dissolution. A commercial excipient supplier can create value through validated mixing guidance, low-variability lubricant grades, and process-specific technical support.

What excipient strategy is best for a POMALYST generic?

A conventional lactose-based capsule is the lowest-risk development path. It can reduce formulation complexity, support rapid manufacturing scale-up, and facilitate comparative dissolution against the reference product.

A generic applicant should evaluate three formulation strategies:

Strategy	Advantages	Main risks	Commercial positioning
Reference-like lactose capsule	Lower development risk and familiar process	Limited differentiation	Volume generic
Lactose-free capsule	Addresses excipient intolerance and broadens formulation flexibility	New blend and bioequivalence work	Premium or specialty generic
Modified wetting system	Potential dissolution or process advantage	Higher CMC and regulatory risk	Technology-driven product

The reference-like approach is likely to dominate price-sensitive markets. Lactose-free or low-surfactant formulations may have value in hospital, specialty-pharmacy, or international markets where prescribers and patients pay closer attention to excipient profiles.

The central development objective is not merely matching the ingredient list. It is matching critical quality attributes, including:

• Assay and content uniformity
• Dissolution across pH conditions
• Capsule-fill weight
• Moisture content
• Impurity profile
• Stability through the proposed shelf life
• Powder flow and segregation resistance

What formulations are protected by POMALYST patents?

Pomalidomide intellectual property has historically focused on the active compound, polymorphs, pharmaceutical compositions, and methods of use rather than on a highly distinctive excipient platform.

The public POMALYST label does not identify an excipient-specific proprietary delivery system.[1] A generic developer therefore should not assume that using lactose, starch, sodium lauryl sulfate, silicon dioxide, or magnesium stearate creates freedom from patent risk. Patent analysis must separate:

1. Pomalidomide compound claims
2. Polymorph and solid-state claims
3. Pharmaceutical composition claims
4. Multiple-myeloma treatment claims
5. Kaposi-sarcoma treatment claims
6. Risk-management and distribution requirements
7. Manufacturing and process claims

The U.S. product is associated with Celgene, now part of Bristol Myers Squibb. The relevant patent estate and Orange Book listings have changed over time as patents expired, were delisted, or became subject to litigation and settlement arrangements. Patent term adjustments and pediatric extensions can also affect the operative date.

Excipient suppliers generally will not receive meaningful freedom-to-operate protection merely by supplying standard compendial materials. Their stronger positions usually come from proprietary grades, particle engineering, manufacturing processes, quality systems, or technical packages rather than from the POMALYST product patents.

When does POMALYST lose exclusivity and what is the generic-entry risk?

POMALYST received FDA approval in 2013 under NDA 204026. Its orphan-drug designation provided seven years of orphan exclusivity for the qualifying indication, which has expired.[2] FDA regulatory exclusivity is distinct from patent protection and does not determine the full generic-entry date.

Pomalidomide is a small molecule, so biosimilar risk does not apply. Competition will proceed through the ANDA pathway, subject to patent certifications, litigation, settlements, and any remaining regulatory or pediatric protection.

Paragraph IV challenges

A generic applicant can file a Paragraph IV certification against listed patents, asserting that a patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation under the Hatch-Waxman framework. A timely infringement action may create a 30-month stay of FDA approval, subject to statutory exceptions and court developments.[3]

For POMALYST, the most material risk is likely to arise from patents covering pomalidomide use, composition, or product-specific claims rather than from the public excipient list. A generic formulation that changes excipients does not avoid active-ingredient or method-of-use patents.

Orange Book status

FDA’s Orange Book identifies approved products, therapeutic equivalence information, listed patents, and certain exclusivity data.[2] Because listings and patent status can change, commercial diligence should use the current Orange Book entry for NDA 204026 and compare it with FDA’s patent-certification and approval records.

An excipient strategy can reduce formulation similarity risk, but it does not eliminate Orange Book exposure. The legal analysis turns on the claims in the listed patents and the proposed ANDA’s labeling, formulation, and use.

What patent litigation and settlement issues affect POMALYST?

Pomalidomide sits within the broader Celgene immunomodulatory-drug portfolio that includes REVLIMID (lenalidomide) and THALOMID (thalidomide). Celgene historically used patent litigation, risk-management controls, and settlement agreements to manage generic competition across this portfolio.

For a POMALYST competitor, settlement terms can be more commercially important than the nominal expiration date of an individual patent. A settlement may define:

• An agreed generic launch date
• Authorized-generic rights
• Restrictions on manufacturing or distribution
• Patent litigation termination
• Inventory and launch conditions
• Allocation of supply or licensing rights

The relevant agreements should be reviewed alongside the Orange Book, FDA approval records, court dockets, and SEC filings by Bristol Myers Squibb. Standard excipient substitution does not alter settlement obligations.

How can excipient suppliers capture commercial opportunities?

Supplying generic manufacturers

The clearest opportunity is supply into ANDA products. A supplier can compete through:

• Lactose monohydrate and pregelatinized starch
• Capsule-grade magnesium stearate
• Pharmaceutical-grade colloidal silicon dioxide
• Gelatin capsule shells
• Titanium dioxide-free color systems where permitted
• Documentation for multiple jurisdictions
• Dual-site supply and business-continuity support

Generic applicants often value regulatory support as much as unit price. DMF availability, change-control discipline, extractables data, allergen statements, nitrosamine assessments, elemental-impurity information, and TSE/BSE documentation can influence supplier selection.

Developing lactose-free platforms

A lactose-free POMALYST-equivalent formulation could use mannitol, microcrystalline cellulose, anhydrous dibasic calcium phosphate, or a multifunctional co-processed excipient. The best candidate would need to preserve capsule size, powder flow, content uniformity, dissolution, and stability.

Mannitol may offer a useful sensory and moisture profile but can alter bulk density and compactability. Microcrystalline cellulose can improve structure but may create different flow and capsule-fill behavior. Co-processed excipients may simplify formulation but can introduce supplier dependence and proprietary documentation requirements.

Improving capsule shells

Capsule suppliers can target:

• Vegetarian hypromellose shells
• Low-moisture gelatin shells
• Titanium dioxide-free white systems
• More stable color matching across strengths
• Tamper-evident or serialization-compatible designs
• Regional compliance with colorant restrictions

A capsule-shell change can affect moisture transfer, brittleness, dissolution, stability, and visual identification. It is commercially attractive but requires comparative performance testing.

Offering manufacturing-IP packages

The most defensible opportunity may be process technology rather than a single excipient. A supplier could protect or commercialize:

• Low-shear blending methods for low-dose pomalidomide
• Segregation-resistant premixes
• Controlled lubricant addition
• Continuous blending
• In-line near-infrared uniformity monitoring
• Encapsulation methods that reduce fill-weight variability

Process know-how can create switching costs without attempting to claim the POMALYST reference formulation itself.

How strong is the POMALYST excipient patent estate?

The public evidence supports a conventional, relatively weakly differentiated excipient estate. The principal barriers are more likely to be:

• Pomalidomide active-ingredient patents
• Method-of-use patents
• Regulatory and distribution controls
• Bioequivalence and content-uniformity requirements
• Manufacturing validation
• Supply-chain qualification

A standard excipient supplier faces low patent risk from the ingredient list alone. A company developing a proprietary excipient system or capsule platform faces greater risk if its product is specifically designed to replicate a patented composition claim.

How does POMALYST compare with REVLIMID and THALOMID?

Product	Active ingredient	Dosage form	Excipient opportunity	Competitive profile
POMALYST	Pomalidomide	Hard capsule	Generic capsule supply, lactose-free reformulation, shell innovation	Small-molecule ANDA competition
REVLIMID	Lenalidomide	Hard capsule	Larger-volume excipient and capsule opportunity	Mature generic and settlement-driven market
THALOMID	Thalidomide	Capsule	Established capsule and global formulation supply	Older product with broader historical use

POMALYST has a smaller commercial base than REVLIMID but may offer higher value per unit because it is used in later-line oncology treatment and specialty distribution channels. Excipient suppliers should prioritize reliability, regulatory execution, and small-batch flexibility over commodity-scale economics.

What is the revenue exposure and commercial outlook?

POMALYST remains commercially relevant because it is an established multiple-myeloma therapy and has an additional FDA-approved indication for AIDS-related Kaposi sarcoma.[1] Revenue exposure is concentrated in oncology, specialty pharmacies, controlled-distribution processes, and reimbursement-sensitive markets.

Generic entry would likely pressure price and gross margin. The impact on excipient suppliers may be positive initially because multiple manufacturers need qualified materials during ANDA scale-up. Over time, price competition will shift demand toward:

• Lower-cost equivalent grades
• Dual-source materials
• Regional manufacturing
• Simplified formulation platforms
• Smaller minimum order quantities
• Faster regulatory-change support

The best commercial position is a qualified, globally documented excipient package that can be adopted by several generic applicants without requiring extensive reformulation.

Key Takeaways

• POMALYST uses a conventional capsule platform centered on lactose monohydrate, pregelatinized starch, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• The public label does not disclose excipient quantities, grades, suppliers, or proprietary delivery technology.
• The main commercial opportunity is supplying generic pomalidomide manufacturers and supporting ANDA formulation development.
• Lactose-free formulations, alternative capsule shells, and controlled-wetting systems provide the strongest differentiation opportunities.
• POMALYST is a small molecule, so biosimilar competition is not relevant.
• Patent risk is concentrated in pomalidomide, composition, method-of-use, and manufacturing claims rather than in the disclosed excipient list.
• Orange Book listings, Paragraph IV certifications, litigation, and settlements determine generic-entry timing.
• Process know-how and regulatory documentation may provide stronger commercial protection than standard excipient composition claims.

FAQs

Can lactose be replaced in a generic POMALYST capsule?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, starch-based systems, or other suitable diluents, but the formulation must meet bioequivalence, dissolution, uniformity, stability, and manufacturing requirements.

Is POMALYST a candidate for a tablet formulation?

Technically, yes, but a tablet would require a new dosage-form development program. The applicant would need to manage dose uniformity, disintegration, dissolution, tablet size, stability, and regulatory comparability. A capsule remains the lower-risk platform.

Does sodium lauryl sulfate create an excipient-based patent barrier?

The disclosed use of sodium lauryl sulfate does not by itself establish a meaningful proprietary barrier. Risk depends on the claims of any relevant composition or formulation patent, not simply on the presence of the excipient.

Are vegetarian POMALYST capsules commercially viable?

They may be viable for a generic or reformulated product if a hypromellose or other non-gelatin shell delivers equivalent stability, dissolution, moisture performance, and product identification. The commercial value is greatest in markets with customer or regulatory preferences against gelatin.

Which excipient suppliers are best positioned for POMALYST generic demand?

Suppliers with reliable pharmaceutical-grade lactose, pregelatinized starch, capsule shells, glidants, and lubricants are best positioned. The strongest suppliers will combine dual-site manufacturing, DMF and quality documentation, low-variability grades, and technical support for low-dose blend uniformity.

References

1. Bristol Myers Squibb. (2024). POMALYST (pomalidomide) capsules: U.S. prescribing information. U.S. Food and Drug Administration.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and generic drug patent certifications. FDA.
4. U.S. Food and Drug Administration. (2024). Approved drugs with orphan-drug designation. FDA.